Measurement of radioactivity in breast milk following 99mTc-Leukoscan injection.
BACKGROUND
There are no published data on the excretion of radioactivity into breast milk following the administration of 99mTc sulesomab (Leukoscan). We report the results of measurements made on breast milk samples from one patient following Leukoscan injection.


RESULTS
The activity concentration in the samples decayed mono-exponentially with an effective half-life of 3.1 h. Based on data from this patient, the interruption period required to reduce the radiation dose to the infant to less than 1 mSv following an administration of 750 MBq 99mTc-leukoscan would be 10 h.


CONCLUSIONS
This information is useful as a guide to the likely period of interruption required when counselling a breastfeeding patient prior to a Leukoscan study.
Prince
Jennie R
JR
North Western Medical Physics, Christie Hospital NHS Trust, Withington, Manchester M20 4BX, UK. jennie.prince@physics.cr.man.ac.uk
Rose
Marge R
MR
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000032:analysis / Q000493:pharmacokinetics*; D058846:Antibodies, Monoclonal, Murine-Derived; D001940:Breast / Q000000981:diagnostic imaging / Q000378:metabolism*; D005260:Female; D006801:Humans; D007267:Injections / Q000379:methods*; D007774:Lactation; D008657:Metabolic Clearance Rate; D008895:Milk, Human / Q000737:chemistry* / Q000378:metabolism*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D019275:Radiopharmaceuticals; C101172:Sulesomab